AI Engines For more Details: Perplexity Kagi Labs You
Antifungal Properties: Enilconazole belongs to the class of azole antifungal agents. It works by inhibiting the synthesis of ergosterol, a crucial component of the fungal cell membrane. By disrupting fungal cell membrane integrity, enilconazole effectively kills or inhibits the growth of the fungus responsible for the infection.
Treatment of Dermatophytosis: Dermatophytosis, commonly known as ringworm, is a contagious fungal infection of the skin, hair, or nails caused by various species of dermatophyte fungi. Enilconazole is specifically indicated for the treatment of ringworm infections in animals, including horses, cattle, dogs, and cats.
Topical Application: Enilconazole is typically administered topically as a solution or shampoo for the treatment of dermatophytosis. It is applied directly to the affected areas of the animal's skin or coat. The frequency and duration of treatment may vary depending on the severity of the infection and the specific instructions provided by the veterinarian.
Efficacy: Enilconazole has demonstrated efficacy in the treatment of dermatophytosis in animals. It is often used as part of a comprehensive management plan that may include topical antifungal therapy, environmental decontamination, and other supportive measures.
Safety Considerations: Enilconazole is generally considered safe and well-tolerated when used according to veterinary recommendations. However, as with any medication, there is a potential for adverse effects, including skin irritation or hypersensitivity reactions at the application site. Care should be taken to avoid contact with the eyes and mucous membranes.
Regulatory Considerations: Enilconazole may be subject to regulatory restrictions or requirements in some regions due to concerns about potential environmental and human health risks associated with its use. Users should adhere to local regulations and guidelines when using enilconazole in veterinary practice.
Veterinary Oversight: Enilconazole is a prescription medication, and its use in animals should be supervised by a licensed veterinarian. Veterinarians are responsible for diagnosing fungal infections, determining appropriate treatment regimens, and monitoring the response to therapy.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 3.8 | 0.9 | 3.22 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 1.8 | 0.56 |
| Allergies | 4.5 | 3.5 | 0.29 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 4.5 | 6.3 | -0.4 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 0.3 | 6.33 |
| Ankylosing spondylitis | 3.3 | 1.8 | 0.83 |
| Anorexia Nervosa | 1.6 | 2.7 | -0.69 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 4.4 | 2 | 1.2 |
| Atherosclerosis | 1.6 | 2 | -0.25 |
| Atrial fibrillation | 3.3 | 2.5 | 0.32 |
| Autism | 8.6 | 8.2 | 0.05 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 2.1 | 2.1 | |
| Bipolar Disorder | 1.8 | 1.4 | 0.29 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.6 | 1.9 | -2.17 |
| Carcinoma | 4.4 | 2.6 | 0.69 |
| Celiac Disease | 2.2 | 2.9 | -0.32 |
| Cerebral Palsy | 1.1 | 1.3 | -0.18 |
| Chronic Fatigue Syndrome | 4.8 | 6.3 | -0.31 |
| Chronic Kidney Disease | 3.1 | 2.9 | 0.07 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 1.7 | 0.24 |
| Chronic Urticaria (Hives) | 0.5 | 0.7 | -0.4 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 6.7 | 2.2 | 2.05 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 2.3 | -0.28 |
| COVID-19 | 7.9 | 11.9 | -0.51 |
| Crohn's Disease | 7.7 | 5.3 | 0.45 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 2 | 1.4 | 0.43 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 9.5 | 7.6 | 0.25 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 2.1 | -0.5 |
| Endometriosis | 2.3 | 1.7 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.3 | 1.1 | 1.09 |
| erectile dysfunction | 2 | 0.3 | 5.67 |
| Fibromyalgia | 3.1 | 2.4 | 0.29 |
| Functional constipation / chronic idiopathic constipation | 4 | 3.8 | 0.05 |
| gallstone disease (gsd) | 2.4 | 1.1 | 1.18 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 1.2 | 0.33 |
| Generalized anxiety disorder | 2.2 | 1.9 | 0.16 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.8 | 0.13 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 1 | -0.11 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.1 | 1.8 | 0.72 |
| Heart Failure | 3.6 | 1.9 | 0.89 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.6 | 1.1 | -0.83 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.5 | 5.3 | -0.51 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 2.4 | 0.9 | 1.67 |
| IgA nephropathy (IgAN) | 1.9 | 3.9 | -1.05 |
| Inflammatory Bowel Disease | 7.7 | 9 | -0.17 |
| Insomnia | 2.2 | 2.1 | 0.05 |
| Intelligence | 1.2 | 0.6 | 1 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 5.7 | 4.3 | 0.33 |
| ischemic stroke | 1.8 | 1.1 | 0.64 |
| Liver Cirrhosis | 6.1 | 3.4 | 0.79 |
| Long COVID | 6.8 | 8.2 | -0.21 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | 1 | -2.33 |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 1.8 | 2.3 | -0.28 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.5 | 0.8 |
| Metabolic Syndrome | 6.7 | 7 | -0.04 |
| Mood Disorders | 8.8 | 6.1 | 0.44 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 6.6 | 6.5 | 0.02 |
| Multiple system atrophy (MSA) | 1.2 | 0.7 | 0.71 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.6 | -7.67 |
| Neuropathy (all types) | 0.7 | 1.6 | -1.29 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.7 | 4.3 | 0.09 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 9.4 | 8.1 | 0.16 |
| obsessive-compulsive disorder | 3.7 | 4.2 | -0.14 |
| Osteoarthritis | 2.6 | 1.2 | 1.17 |
| Osteoporosis | 1.6 | 1.3 | 0.23 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 6.6 | 6.5 | 0.02 |
| Polycystic ovary syndrome | 6.2 | 3.2 | 0.94 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.5 | -0.67 |
| Primary sclerosing cholangitis | 2.1 | 3.2 | -0.52 |
| Psoriasis | 2.5 | 3.3 | -0.32 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.9 | 3.9 | 1.03 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 5.7 | 2.8 | 1.04 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 1.7 | 3.1 | -0.82 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0 | 0 |
| Stress / posttraumatic stress disorder | 2.6 | 2.5 | 0.04 |
| Systemic Lupus Erythematosus | 3.5 | 2.1 | 0.67 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.5 | 3.8 | -0.52 |
| Type 2 Diabetes | 7.7 | 7 | 0.1 |
| Ulcerative colitis | 5 | 5.9 | -0.18 |
| Unhealthy Ageing | 5.4 | 2.4 | 1.25 |
| Vitiligo | 2 | 1.5 | 0.33 |
